Recombinant adeno-associated viral vector-mediated glial cell line- derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease

Experimental Neurology

Volumn 160, Issue 1, 1999, Pages 205-214

  Mandel, R J ^a   Snyder, R O ^b   Leff, S E ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CELL GENESYS INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Gene therapy; Neurodegeneration; Retrograde tracing; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TRANSGENE;

EID: 0032708890     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7203     Document Type: Article

References (56)

1. Anglade P., Vyas S., Javoy-Agid F., Herrero M. T., Michel P. P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E. C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
2. Barbeau A. Dopamine and dopamine metabolites in Parkinson's disease - A review. Proc. Aust. Assoc. Neurol. 5:1968;95-100.
3. Bartlett J. S., Samulski R. J., McCown T. J. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 9:1998;1181-1186.
4. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.-J., Mallet J., Horellou P. Intrastriatal injection of an adenoviral vector expression glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA. 94:1997;8818-8823.
5. Björklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4:1997;186-200.
6. Bohn M. C. A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy. Biochem. Pharmacol. 57:1999;135-142.
7. Bohn, M. C., and D. L. Choi-Lundberg. 1998. Gene therapies for Parkinson's disease. In Gene Therapy for Neurological Disorders and Brain TumorsE. A. Chiocca and X. O. Breakfield, Eds., pp. 377-395. Humana Press, Totowa, NJ.
8. Bowenkamp K. E., David D., Lapchak P. L., Henry M. A., Granholm A. C., Hoffer B. J., Mahalik T. J. 6-Hydroxy-dopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp. Brain Res. 111:1996;1-7.
9. Bowenkamp K. E., Hoffman A. F., Gerhardt G. A., Henry M. A., Biddle P. T., Hoffer B. J., Granholm A. C. E. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355:1995;479-489.
10. Bowenkamp K. E., Lapchak P. A., Hoffer B. J., Bickford P. C. Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. Neurosci. Lett. 211:1996;81-84.
11. Choi-Lundberg D. L., Lin Q., Chang L.-N., Chiang L., Hay C. M., Mohajeri H., Davidson B. L., Bohn M. C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 275:1997;838-841.
12. Choi-Lundberg D. L., Lin Q., Schallert T., Crippens D., Davidson B. L., Chang Y. N., Chiang Y. L., Qian J., Bardwaj L., Bohn M. C. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154:1998;261-275.
13. Clarkson E. D., Zawada W. M., Freed C. R. GDNF reduces apoptosis in dopaminergic neurons in vitro. Neuroreport. 7:1995;145-149.
14. Clarkson E. D., Zawada W. M., Freed C. R. GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Cell Tissue Res. 289:1997;207-210.
15. Dwarki V. J., Belloni P., Nijjar T., Smith J., Couto L., Rabier M., Clift S., Berns A., Cohen L. K. Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. USA. 92:1995;1023-1027.
16. Ferrari F. K., Samulski T., Shenk T., Samulski R. J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:1996;3227-3234.
17. Flannery J. G., Zolotukhin S., Vaquero M. I., Lavail M. M., Muzyczka N., Hauswirth W. W. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA. 94:1997;6916-6921.
18. Gash D. M., Zhang Z. M., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
19. Herzog R. W., Hagstrom J. N., Kung S. H., Tai S. J., Wilson J. M., Fisher K. J., High K. A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA. 94:1997;5804-5809.
20. Herzog R. W., Yang E. Y., Couto L. B., Hagstrom J. N., Elwell D., Fields P. A., Burton M., Bellinger D. A., Read M. S., Brinkhous K. M., Podsakoff G. M., Nichols T. C., Kurtzman G. J., High K. A. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5:1999;56-63.
21. Horger B., Nishimura M., Armanini M., Wang L.-C., Poulsen K., Rosenblad C., Kirik D., Moffat B., Simmons L., Johnson E., Milbrandt J., Rosenthal A., Björkland A., Vandlen R., Hynes M., Phillips H. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18:1998;4929-4937.
22. Hudson J., Granholm A. C., Gerhardt G. A., Henry M. A., Hoffman A., Biddle P., Leela N. S., Mackerlova L., Lile J. D., Collins F., Hoffer B. J. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36:1995;425-432.
23. Kearns C. M., Cass W. A., Smoot K., Kryscio R., Gash D. M. GDNF protection against 6-OHDA: Time dependence and requirement for protein synthesis. J. Neurosci. 17:1997;7111-7118.
24. Kessler P. D., Podsakoff G. M., Chen X., McQuiston S. A., Colosi P. C., Matelis L. A., Kurtzman G. J., Byrne B. J. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA. 93:1996;14082-14087.
25. Kirk R. E. Experimental Design: Procedures for the Behavioral Sciences. 1968;Brooks/Cole, Belmont.
26. Klein R. L., Meyer E. M., Peel A. L., Zolotukhin S., Meyers C., Muzyczka N., King M. A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150:1998;183-194.
27. Lapchak P. A., Araujo D. M., Hilt D. C., Sheng J., Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res. 777:1997;153-160.
28. Leff S. E., Spratt S. K., Snyder R. O., Mandel R. J. Restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated virus in an animal model of Parkinson's disease. Neuroscience. 92:1999;187-198.
29. Lotharius J., Dugan L. L., O'Malley K. L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19:1999;1284-1293.
30. Lu X., Hagg T. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. J. Comp. Neurol. 388:1997;484-494.
31. Mandel R. J., Rendahl K. G., Spratt K. S., Snyder R. O., Cohen L. K., Leff S. E. Characterization of intrastriatal recombinant adeno-associated virus mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydroxylase I in a rat model of Parkinson's disease. J. Neurosci. 18:1998;4271-4284.
32. Mandel R. J., Spratt S. K., Snyder R. O., Leff S. E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA. 94:1997;14083-14088.
33. McCown T. J., Xiao X., Li J., Breese G. R., Samulski R. J. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713:1996;99-107.
34. McGeer P. L., Itagaki S., Akiyama H., McGeer E. G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24:1988;574-576.
35. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137:1996;120-123.
36. Offen D., Beart P. M., Cheung N. S., Pascoe C. J., Hochman A., Gorodin S., Melamed E., Bernard R., Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA. 85:1998;5789-5794.
37. Ory D. S., Neugeboren B. A., Mulligan R. C. A stable human-derived packaging cell line for production of high titre retrovirus/vesicular stomatitis virus G psuedotypes. Proc. Natl. Acad. Sci. USA. 93:1996;11382-11388.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1987;Academic Press, San Diego.
39. Rendahl K. G., Leff S. E., Otten G. R., Spratt S. K., Bohl D., Roey M. V., Donahue B. A., Cohen L. K., Mandel R. J., Danos O., Snyder R. O. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat. Biotechnol. 16:1998;757-761.
40. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H. S., Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11:1999;1554-1566.
41. Rosenblad C., Martínez-Serrano A., Björklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 82:1997;129-137.
42. Ruberg M., Brugg B., Prigent A., Hirsch E., Brice A., Agid Y. Is differential regulation of mitochondrial transcripts in Parkinson's disease related to apoptosis. J. Neurochem. 68:1997;2098-2110.
43. Sauer H., Oertel W. H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-Hydroxydopamine - A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
44. Sauer H., Rosenblad C., Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. USA. 92:1995;8935-8939.
45. Snyder R. O., Miao C., Meuse L., Tubb J., Donahue B. A., Lin H. F., Stafford D. W., Patel S., Thompson A. R., Nichols T., Read M. S., Bellinger D. A., Brinkhous K. M., Kay M. A. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5:1999;64-70.
46. Snyder R. O., Miao C. H., Patijn G. A., Spratt S. K., Danos O., Gown A. M., Winther B., Meuse L., Cohen L. K., Thompson A. R., Kay M. A. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16:1997;270-276.
47. Snyder R. O., Spratt S. K., Lagarde C., Bohl D., Kaspar B., Sloan B., Cohen L. K., Danos O. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8:1997;1891-1900.
48. Snyder, R. O., X. Xiao, and R. J. Samulski. 1996. Production of recombinant adeno-associated viral vectors. In Current Protocols in Human GeneticsN. Dracopoli, J. Haines, B. Krof, D. Moir, C. Morton, C. Seidman, J. Seidman, and D. Smith, Eds., pp. 1-24. Wiley, New York.
49. Sternberger L. A., Hardy P. H., Cuculis J. J., Meyer H. G. The unlabelled antibody-enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in the identification of spirochetes. J. Histochem. Cytochem. 18:1970;315-333.
50. Szczypka M. S., Mandel R. J., Donahue B. A., Snyder R. O., Leff S. E., Palmiter R. D. Viral gene therapy selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron. 22:1999;167-178.
51. Tanner C. M., Ottman R., Goldman S. M., Ellenberg J., Chan P., Mayeux R., Langston J. W. Parkinson disease in twins: An etiologic study. J. Am. Med. Assoc. 281:1999;341-346.
52. Tompkins M. M., Basgall E. J., Zamrini E., Hill W. D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigra neurons. Am. J. Pathol. 150:1997;119-131.
53. Tseng J. L., Baetge E. E., Zurn A. D., Aebischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17:1997;325-333.
54. Walkinshaw G., Waters C. M. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience. 63:1994;975-987.
55. Winkler C., Sauer H., Lee C. S., Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16:1996;7206-7215.
56. Ye X., Rivera V. M., Zoltick P., Cerasoli F. Jr., Schnell M. A., Gao G., Hughes J. V., Gilman M., Wilson J. M. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 283:1999;88-91.